156 related articles for article (PubMed ID: 26739479)
1. A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
Clark SL; Nystrom EM
J Pharm Pract; 2016 Apr; 29(2):172-6. PubMed ID: 26739479
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
[TBL] [Abstract][Full Text] [Related]
3. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
Kaur U; Chakrabarti SS; Gambhir IS
Curr Drug Saf; 2016; 11(3):267-9. PubMed ID: 27113952
[TBL] [Abstract][Full Text] [Related]
4. Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases.
Kilci F; Jones JH; Çizmecioğlu-Jones FM
J Clin Res Pediatr Endocrinol; 2024 May; 16(2):224-228. PubMed ID: 36264042
[TBL] [Abstract][Full Text] [Related]
5. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
6. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Dincer M; Altundag K; Harputluoglu H; Aksoy S; Cengiz M; Gullu I
Med Oncol; 2008; 25(3):356-9. PubMed ID: 18196480
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
8. Severe Hypophosphatemia as the Initial Presentation of Renal Fanconi's Syndrome and Distal Renal Tubular Acidosis Related to Zoledronic Acid: A Case Report and Literature Review.
Wu Y; Ma T; Yu X; Su T
Kidney Blood Press Res; 2023; 48(1):18-27. PubMed ID: 36412607
[TBL] [Abstract][Full Text] [Related]
9. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
[TBL] [Abstract][Full Text] [Related]
10. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
11. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
Shen G; Song ST; Jiang ZF; Bian SG; Xie GR; Wang YJ; Wang JJ
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):632-4. PubMed ID: 16438878
[TBL] [Abstract][Full Text] [Related]
13. Electrolyte abnormalities with zoledronic acid therapy.
Sorscher SM
Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
[No Abstract] [Full Text] [Related]
14. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
[TBL] [Abstract][Full Text] [Related]
15. Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting.
Fan W; Leder BZ; Mannstadt M; Ly TV; Franco-Garcia E; Bolster MB
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1282-e1288. PubMed ID: 37227016
[TBL] [Abstract][Full Text] [Related]
16. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Sonis ST; Watkins BA; Lyng GD; Lerman MA; Anderson KC
Oral Oncol; 2009 Feb; 45(2):164-72. PubMed ID: 18715819
[TBL] [Abstract][Full Text] [Related]
17. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs.
Brewer DJ; Macfarlane M; O'Connell E; Bacon NJ
J Vet Intern Med; 2022 Jan; 36(1):253-258. PubMed ID: 34859920
[TBL] [Abstract][Full Text] [Related]
19. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
20. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
